Heron Therapeutics Inc. (NASDAQ:HRTX) fell 1.8% during mid-day trading on Thursday . The company traded as low as $20.68 and last traded at $20.80, with a volume of 297,659 shares trading hands. The stock had previously closed at $21.19.

A number of research firms recently issued reports on HRTX. Cantor Fitzgerald began coverage on shares of Heron Therapeutics in a research note on Monday, May 2nd. They set a “buy” rating and a $41.00 price target on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, April 28th. Leerink Swann reissued an “outperform” rating and issued a $33.00 target price on shares of Heron Therapeutics in a research note on Thursday. Brean Capital reissued a “buy” rating and issued a $55.00 target price on shares of Heron Therapeutics in a research note on Saturday, August 13th. Finally, Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $47.70.

The company has a 50-day moving average of $18.30 and a 200-day moving average of $18.81.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Analysts predict that Heron Therapeutics Inc. will post ($4.39) earnings per share for the current fiscal year.

In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the sale, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

An institutional investor recently bought a new position in Heron Therapeutics stock. Bank of Montreal Can bought a new stake in Heron Therapeutics Inc. (NASDAQ:HRTX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 112,720 shares of the biotechnology company’s stock, valued at approximately $3,010,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.